Are Sunscreens Safe? Absorption, Allergy and Australian Guidance

Written by

in

TANRUB JOURNAL · RESEARCH & SUN PROTECTION

Sunscreen absorption is measurable, but finding an ingredient in blood does not establish that normal sunscreen use causes harm. Here is what the research can—and cannot—tell us.

By Tanrub · Sources checked 10 October 2026 · Editorial research summary

What the absorption studies actually measured

FDA researchers investigated how much of selected sunscreen ingredients entered the bloodstream under controlled use. The 2019 pilot involved 24 participants and four sunscreen products; a 2020 follow-up studied 48 participants and six active ingredients. Both found absorption above a regulatory threshold used to trigger additional safety testing.

The threshold of 0.5 ng/mL is not a demonstrated toxicity boundary. Crossing it does not show that the ingredient causes cancer or that sunscreen should be abandoned. These were pharmacokinetic studies, rather than trials designed to measure long-term disease. The follow-up authors explicitly cautioned that their findings did not mean people should stop using sunscreen.

What the Australian regulator found

The TGA’s 2025 review evaluated seven active ingredients. Five were considered low risk on the available evidence. For homosalate and oxybenzone, the regulator recommended controls on permitted concentrations and use. Its subsequent public advice continued to favour sunscreen use because the established benefits outweigh the potential risks.

A recommendation or consultation is not the same as a ban or a recall. Ingredient reviews and product-specific notices also address different questions. Check the TGA’s current sunscreen resources for any updates affecting a product you own, rather than treating an older research summary as a complete regulatory record.

Absorption, irritation and allergy are different questions

A skin reaction does not prove a systemic toxic effect. Burning, redness or itching may reflect irritation, allergic contact dermatitis, fragrance sensitivity or a reaction involving sunlight. Specialist patch and photopatch testing can help distinguish these possibilities.

The original review cited small or selected groups of patients referred for testing. Their reaction rates cannot be used as the risk for the general population. Oxybenzone is a recognised potential allergen, but it is not the only ingredient worth considering. Avoid interpreting a rash from one formula as proof that every sunscreen is unsuitable.

Does a higher SPF mean a less safe formula?

SPF is a protection measure, not an ingredient-safety score. You cannot infer total absorption, allergy risk or toxicity simply from the SPF number. Products differ in their filters, concentrations, solvents, fragrances and application patterns. The supplied article did not establish a clinical comparison of ingredient safety across SPF30, SPF50 and SPF100.

Claims that every higher-SPF formula necessarily gives a more concerning chemical exposure are therefore too broad. If you are sensitive to a particular ingredient, compare the actual formulation and discuss suitable alternatives with a pharmacist or clinician.

A practical approach to product choice

  • Choose a product suitable for your skin that you can apply consistently.
  • Read its active ingredients, expiry date, storage and application instructions.
  • If a product causes a reaction, stop using that formula and seek advice rather than giving up sun protection.
  • Ask a pharmacist or dermatologist about alternatives if you have recurring reactions or a known allergy.

Cancer Council Australia recommends broad-spectrum, water-resistant SPF50 or SPF50+ when UV levels are 3 or above, together with clothing, a hat, shade and sunglasses. A product you tolerate still needs correct application; sunscreen alone is not complete protection.

What remains uncertain

Small short-term absorption studies do not resolve every question about lifelong use, all formulations or all population groups. Equally, an unanswered research question is not evidence of a clinical harm. This article distinguishes established UV risks from the limitations of current ingredient studies.

Sources

  1. Matta et al., JAMA 2019: maximal-use absorption trial.
  2. Matta et al., JAMA 2020: follow-up absorption trial.
  3. TGA: safety review of seven active sunscreen ingredients.
  4. TGA: advice accompanying proposed additional controls.
  5. Cancer Council Australia: sunscreen guidance.

Continue reading

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *